natgillin/translations-raw huggingface dataset:
• Check (just after removing from the refrigerator) that the cartridge is not accidentally frozen in the pack or inside the device. 
• Preverite, da vložek (ko ga odstranite iz hladilnika) ni po nesreči zamrznil v škatli ali znotraj pripomočka.
• use an aseptic injection technique, 
• uporabljajo aseptično tehniko injiciranja
If you use RebiSmart • RebiSmart is programmed to guide you through the entire initiation process and automatically increases the dose during the initiation period. 
• Pripomoček RebiSmart je programiran tako, da vas vodi skozi celotni začetni postopek in samodejno povečuje odmerek v začetnem obdobju.
It is recommended that patients should be evaluated at least every second year in the 4-year period after initiation of treatment with Rebif and a decision for longer term treatment should then be made on an individual basis by the treating physician. 
Zato se priporoča, da lečeči zdravnik bolnika pregleda najmanj vsako drugo leto v 4-letnem obdobju od začetka zdravljenja z zdravilom Rebif in na individualni osnovi sprejme odločitev o dolgoročnem zdravljenju.
It has been shown to reduce the number and the severity of relapses and to slow the progression of disability. 
Dokazano je, da zmanjšuje število in jakost zagonov te bolezni ter upočasnjuje napredovanje nesposobnosti.
• Blood clots such as deep venous thrombosis 
• krvni strdki, kot je globoka venska tromboza
The injection site can become infected (uncommon); the skin may become swollen tender and hard and the whole area could be very painful. 
Mesto injiciranja se lahko okuži (občasno); koža lahko postane otekla, občutljiva in trda, celotni predel je lahko zelo boleč.
Patients with single lesions may continue provided that the necrosis is not too extensive. 
Bolniki, ki imajo eno samo lezijo, lahko z zdravljenjem nadaljujejo pod pogojem, da nekroza ni preobširna.
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. PROIZVAJALEC BIOLOŠKE UČINKOVINE IN PROIZVAJALEC , ODGOVOREN ZA SPROŠČANJE SERIJ
• Insert the needle into the skin as you have been told by your doctor. 
•Zabodite iglo v kožo, kot vas je poučil vaš zdravnik.
In some cases such symptoms are associated with fever or flu-like symptoms described above. 
V nekaterih primerih se takšni znaki lahko pojavijo v povezavi z zvišano telesno temperaturo ali gripi podobnimi znaki, ki so opisani zgoraj.
For multidose use. 
Za večkratno uporabo.
These results obtained in a subgroup of patients a posteriori should be interpreted cautiously. 
Pri interpretaciji rezultatov iz podskupine bolnikov a posteriori je potrebna previdnost.
* Million International Units, measured by cytopathic effect (CPE) bioassay against the in-house interferon beta-1a standard which is calibrated against the current international NIH standard (GB-23-902-531). 
* milijon mednarodnih enot, merjeno z biološkim testom s citopatskim učinkom (CPE) po standardu proizvajalca za interferon beta-1a, ki je kalibriran po trenutnem mednarodnem NIH standardu (GB-23-902-531).
The safety and efficacy of Rebif in children below 2 years of age have not yet been established. 
Varnost in učinkovitost zdravila Rebif pri otrocih, starih manj kot 2 leti, še nista bili dokazani.
You should not discontinue the treatment without first contacting your doctor. 
Zdravljenja ne smete prekiniti, ne da bi se predhodno posvetovali z zdravnikom.
Therefore, in addition to those laboratory tests normally required for monitoring patients with multiple sclerosis, liver enzyme monitoring and complete and differential blood cell counts and platelet counts are recommended at regular intervals (1, 3 and 6 months) following introduction of Rebif therapy and then periodically thereafter in the absence of clinical symptoms. 
Zato se poleg tistih laboratorijskih testov, ki so normalno potrebni za spremljanje bolnikov z multiplo sklerozo, priporoča spremljanje testov jetrne funkcije in spremljanje celotne in diferencialne krvne slike ter števila trombocitov v rednih časovnih razmakih (1, 3 in 6 mesecev) po začetku zdravljenja z zdravilom Rebif in nato periodično, če ni kliničnih znakov.
• Full instructions for use are provided with your device. 
• Izčrpna navodila za uporabo so priložena vašemu pripomočku.
Rebif has not been investigated for carcinogenicity. 
Zdravila Rebif niso preizkušali na kancerogenost.
The use of various assays to detect serum antibodies and differing definitions of antibody positivity limits the ability to compare antigenicity among different products. 
Uporaba različnih testov za dokazovanje serumskih protiteles in različne definicije mej za pozitivnost protiteles omejujejo možnost primerjave antigenskih lastnosti med različnimi zdravili.
If you experience symptoms suggesting a liver disorder, such as loss of appetite accompanied by other symptoms such as nausea, vomiting, jaundice, please contact your doctor immediately (see above “Tell your doctor immediately...”). 
Če imate znake, ki kažejo na motnje v delovanju jeter, kot so izguba apetita, ki ga spremljajo drugi znaki, kot so siljenje na bruhanje, bruhanje, zlatenica, se prosimo takoj posvetujte s svojim zdravnikom (glejte zgoraj »Takoj obvestite svojega zdravnika...«).
Below is a picture showing what RebiDose looks like. 
Spodnja slikakaže kako izgleda peresnik RebiDose.
Very common (may affect more than 1 in 10 people): • Headache 
Zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov): • glavobol
Severe liver problems can be associated with additional signs, e.g. difficulty concentrating, sleepiness and confusion. 
Hude težave z jetri lahko spremljajo dodatni znaki kot so težave s koncentracijo, zaspanost in zmedenost.
Efficacy has not been demonstrated in patients with secondary progressive multiple sclerosis without ongoing relapse activity (see section 5.1). 
Učinkovitost ni bila ugotovljena pri bolnikih s sekundarno progresivno multiplo sklerozo, ki nimajo aktivnih zagonov (glejte poglavje 5.1).
If TMA is diagnosed, prompt treatment is required (considering plasma exchange) and immediate discontinuation of Rebif is recommended. 
Če je TMA diagnosticirana, je potrebno takojšnje zdravljenje (razmisliti o izmenjavi plazme), priporoča pa se tudi takojšnje prenehanje zdravljenja z zdravilom Rebif.
If you miss a dose, continue to inject from the day of the next scheduled dose. 
Če ste izpustili odmerek, nadaljujte z injekcijami z dnevom, predvidenim za naslednji odmerek.
The procedure for the self-administration by the patient should be reviewed periodically especially if injection site reactions have occurred. 
Periodično moramo preverjati postopek samoinjiciranja, še posebej pri bolnikih, pri katerih so se pojavile reakcije na mestu injiciranja.
Efficacy results of Rebif 44 micrograms given three times per week compared to placebo from this study are as follows: 
Rezultati učinkovitosti zdravila Rebif 44 mikrogramov, dajanega trikrat na teden v primerjavi s placebom v tej študiji so:
• or if you have experienced depression, 
• ste bili v depresiji,
The devices are provided separately. 
Pripomočka sta na voljo posebej.
• MS pseudo-relapse (frequency not known): There is a possibility that at the beginning of your treatment with Rebif you may experience symptoms that resemble those of a multiple sclerosis relapse. 
• Navidezni ponovni zagon MS (pogostnost ni znana): Obstaja možnost, da boste na začetku zdravljenja z zdravilom Rebif opazili znake, ki so podobni znakom ponovnega zagona multiple skleroze.
Limited information available on the transfer of interferon beta-1a into breast milk, together with the chemical/physiological characteristics of interferon beta, suggests that levels of interferon beta-1a excreted in human milk are negligible. 
Omejeni podatki o prehajanju interferona beta-1a v materino mleko, skupaj s kemičnimi/fiziloškimi značilnostmi interferona beta kažejo, da so ravni interferona beta-1a, ki se izločijo v materino mleko, zanemarljive.
• Inform your doctor immediately if you experience any of the following possible symptoms of a liver problem: jaundice (yellowing of the skin or of the whites of the eyes), widespread itching, loss of appetite accompanied by nausea and vomiting and easy bruising of the skin. 
• Takoj obvestite svojega zdravnika, če ste opazili katerega od sledečih možnih znakov, ki kažejo na težave z jetri: zlatenica (porumenelost kože ali beločnic), splošno srbenje, izguba apetita, ki jo spremljajo siljenje na bruhanje in bruhanje ter pojav manjših podplutb na koži.
• Gently pinch the skin together around the site (to lift it up a bit). 
• Nežno stisnite kožo okoli mesta (da jo malce dvignete).
Patients treated with Rebif should be advised to immediately report any symptoms of depression and/or suicidal ideation to their prescribing physician. 
Bolnike, ki se zdravijo z zdravilom Rebif, moramo opozoriti, da o morebitnih znakih depresije in/ali samomorilskih mislih takoj poročajo svojemu zdravniku.
The carton contains a package leaflet with full instructions for use and handling. 
V škatli je navodilo za uporabo s popolnimi navodili za uporabo in ravnanje z zdravilom.
From the fifth week onwards, after you have completed your initiation period, you will follow the usual dose regimen prescribed by your doctor. 
Od petega tedna naprej, ko boste zaključili uvajalno obdobje, boste sledili običajnemu režimu odmerjanja, ki vam ga je predpisal vaš zdravnik.
• Check the appearance of Rebif through the transparent window. 
• Preverite videz zdravila Rebif skozi prozorno okence.
Following repeated subcutaneous injections of 22 and 44 micrograms doses of Rebif maximum concentrations were typically observed after 8 hours, but this was highly variable. 
Po ponavljajočih subkutanih injekcijah odmerkov z 22 in 44 mikrogrami zdravila Rebif so največje koncentracije običajno opazili po 8 urah, vendar se je to med bolniki močno razlikovalo.
The majority of adverse reactions observed with interferon beta-1a are usually mild and reversible, and respond well to dose reductions. 
Večina neželenih učinkov, opaženih pri interferonu beta-1a, je običajno blagih in reverzibilnih in se dobro odzivajo na zmanjšanje odmerka.
Dose reduction of Rebif should be considered if ALT rises above 5 times the ULN, and gradually re-escalated when enzyme levels have normalized. 
Pretehtati moramo potrebo po zmanjšanju odmerka zdravila Rebif, če ALT naraste čez 5-kratno ULN in nato odmerek postopoma povečevati, ko se raven encimov normalizira.
If tests are normal at baseline, routine testing is not needed but should be performed if clinical findings of thyroid dysfunction appear (see section 4.8). 
Če so vrednosti testov ob pričetku normalne, rutinske preiskave niso potrebne, vendar se morajo izvajati, če se pojavijo klinični znaki motenj delovanja ščitnice (glejte poglavje 4.8).
• You will need to select the dose prescribed by your doctor via the RebiSmart menu to ensure the correct recording of your dose. 
• Na meniju pripomočka RebiSmart boste morali izbrati odmerek, ki vam ga je predpisal zdravnik, s čimer zagotovite pravilno zapisovanje vašega odmerka.
The thyroid gland may function either excessively, or insufficiently. 
Delovanje ščitnice je lahko preveliko ali premajhno.
Quincke's oedema (angio-oedema)*, erythema multiforme*, erythema multiforme-like skin reactions*, Stevens Johnson syndrome* Musculoskeletal and connective disorders Common: 
Quinckejev edem (angioedem)*, multiformni eritem*, multiformnemu eritemu podobne kožne reakcije*, Stevens-Johnsonov sindrom* Bolezni mišično-skeletnega sistema in vezivnega tkiva Pogosti:
• Dilatation of the blood vessels and palpitation 
• dilataciji krvnih žil in palpitaciji
In clinical trials with Rebif, asymptomatic elevations of hepatic transaminases (particularly alanine aminotransferase (ALT)) were common and 1-3% of patients developed elevations of hepatic transaminases above 5 times the upper limit of normal (ULN). 
V kliničnih študijah z zdravilom Rebif je bilo pogosto asimptomatsko zvišanje jetrnih transaminaz (zlasti alanin-aminotransferaze (ALT)) in 1-3 % bolnikov je razvilo povečanje jetrnih transaminaz, ki je preseglo 5-kratne vrednosti zgornje meje normalne ravni (ULN).
If you have poor vision you should not use RebiSlide unless someone with good eyesight can provide support. 
Če slabo vidite, ne smete uporabljati pripomočka RebiSlide, razen če vam pomaga oseba, ki nima težav z vidom.
** produced in Chinese hamster ovary Cells (CHO-K1) by recombinant DNA technology. 
** pridobljen s tehnologijo rekombinantne DNK na ovarijskih celicah kitajskega hrčka (CHO-K1).
It is recommended that you keep track of and rotate your injection sites, so that one area is not injected too frequently in order to minimise the risk of injection site necrosis. 
Priporočljivo je, da si beležite mesta injiciranja in jih izmenjujete tako, da ne zabadate prepogosto v eno in isto mesto, da zmanjšate tveganje za nekrozo na mestu injiciranja.
Approximately 70% of patients treated with Rebif can expect to experience the typical interferon flu-like syndrome within the first six months after starting treatment. 
Približno 70 % bolnikov zdravljenih z zdravilom Rebif lahko pričakuje pojav za interferon značilnega gripi podobnega sindroma v prvih šestih mesecih po začetku zdravljenja.
Approximately 30% of patients will also experience reactions at the injection site, predominantly mild inflammation or erythema. 
Približno 30 % bolnikov bo izkusilo tudi reakcije na mestu injiciranja, pretežno blago vnetje ali eritem.
Hepatic failure* (see section 4.4), autoimmune hepatitis* 
jetrna odpoved* (glejte poglavje 4.4), avtoimuni hepatitis*
Do not use Rebif 
Ne uporabljajte zdravila Rebif
For the time being there is no well established definition of a high risk patient, although a more conservative approach is to accept at least nine T2 hyperintense lesions on the initial scan and at least one new T2 or one new Gd-enhancing lesion on a follow-up scan taken at least 1 month after the initial scan. 
Trenutno ni uveljavljene definicije bolnikov z visokim tveganjem, čeprav se po bolj konzervativnem pristopu sprejme vsaj devet hiperintenzivnih T2-lezij na začetnem posnetku in vsaj ena nova T2 ali ena nova z gadolinijem vidna lezija na naslednjem posnetku, ki je narejen vsaj 1 mesec po začetnem posnetku.
In the absence of clinical symptoms, serum ALT levels should be monitored prior to the start of therapy, at months 1, 3 and 6 on therapy and periodically thereafter. 
Če ni kliničnih znakov, moramo nadzirati serumsko raven ALT pred začetkom zdravljenja, po 1, 3 in 6 mesecih zdravljenja in nato periodično.
Rebif should be initiated with caution in patients with a history of significant liver disease, clinical evidence of active liver disease, alcohol abuse or increased serum ALT (>2.5 times ULN). 
Zdravljenje z zdravilom Rebif moramo uvajati previdno pri bolnikih s pomembnimi jetrnimi boleznimi v anamnezi, s klinično potrjeno aktivno jetrno boleznijo, zlorabo alkohola ali zvišano serumsko ravnjo ALT (>2,5-kratna ULN).
Nephrotic syndrome*, glomerulosclerosis* (see section 4.4) General disorders and administration site conditions Very common: 
nefrotski sindrom*, glomeruloskleroza* (glejte poglavje 4.4) Splošne težave in spremembe na mestu aplikacije Zelo pogosti:
Caution should be exercised when administering Rebif in combination with medicinal products that have a narrow therapeutic index and are largely dependent on the hepatic cytochrome P450 system for clearance, e.g. antiepileptics and some classes of antidepressants. 
Previdnost se zahteva pri uporabi zdravila Rebif v kombinaciji z zdravili, ki imajo ozek terapevtski indeks in se v glavnem razgrajujejo preko jetrnega citokrom P450 sistema, npr. antiepileptiki in nekatere vrste antidepresivov.
Cessation of therapy with Rebif should be considered (see sections 4.3 and 4.8). 
Proučiti moramo možnost prenehanja zdravljenja z zdravilom Rebif (glejte poglavji 4.3 in 4.8).
To minimise the risk of injection site necrosis patients should be advised to: 
Za zmanjševanje tveganja nastanka nekroz na mestu injiciranja, moramo bolnikom svetovati, da:
The overall incidence of these is slightly higher with Rebif 44 than Rebif 22 micrograms. 
Celokupna incidenca le-teh je nekoliko višja pri zdravilu Rebif 44 mikrogramov kot pri zdravilu Rebif 22 mikrogramov.
Only sparse safety and efficacy data are available from non-ambulatory patients with multiple sclerosis. 
Podatki o varnosti in učinkovitosti pri neambulantnih bolnikih z multiplo sklerozo so omejeni.
• Resting your wrist on the skin near the site, stick the needle at a right angle straight into the skin with a quick, firm motion. 
• Z zapestjem naslonjenim na kožo v bližini mesta, s hitrim in trdnim gibom zabodite iglo pod pravim kotom naravnost v kožo.
Prior to injection and for an additional 24 hours after each injection, an antipyretic analgesic is advised to decrease flu-like symptoms associated with Rebif administration. 
Pred injiciranjem in še naslednjih 24 ur po vsaki injekciji je priporočena uporaba antipiretičnega analgetika za zmanjševanje gripi podobnih simptomov, povezanih z uporabo zdravila Rebif.
• Blood clots in the small blood vessels that can affect your kidneys (thrombotic thrombocytopenic purpura or haemolytic uremic syndrome). 
• Krvni strdki v majhnih krvnih žilah, ki lahko vplivajo na delovanje ledvic (trombotična trombocitopenična purpura ali hemolitično-uremični sindrom).
These reactions are rare (may affect up to 1 in 1,000 people). 
Te reakcije so redke (pojavijo se lahko pri največ 1 od 1.000 bolnikov).
• Inject the medicine by using a slow, steady push (push the plunger all the way in until the syringe is empty). 
• S počasnim in enakomernim pritiskom vbrizgajte zdravilo (potiskajte bat do konca, dokler injekcijska brizga ni prazna).
If, immediately following Rebif administration you experience a sudden difficulty breathing, which may appear in association with swelling of face, lips, tongue or throat, nettle rash, itching all over the body, and a feeling of weakness or faintness, contact your doctor immediately or seek urgent medical attention. 
Če takoj po dajanju zdravila Rebif začutite nenadne težave z dihanjem, ki se lahko pojavijo skupaj z otekanjem obraza, ustnic, jezika ali žrela, koprivnico, srbenjem po celem telesu in z občutkom šibkosti ali omedlevice, se takoj posvetujte s svojim zdravnikom ali poiščite nujno zdravniško pomoč.
Mean CUA Lesions per Subject per Scan During the Double Blind Period Least Square Means (SE) * tiw - three times per week 
Srednje lezije CUA na osebo in na slikanje v dvojno slepem obdobju Srednja vrednost po metodi najmanjših kvadratov (SE) * tiw - trikrat na teden
• Epileptic seizures 
• epileptični napadi
Patients with cardiac disease, such as angina, congestive heart failure or arrhythmia, should be closely monitored for worsening of their clinical condition during initiation of therapy with interferon beta-1a. 
Bolnike s srčnimi boleznimi, kot so angina pektoris, kongestivno srčno popuščanje ali aritmija, moramo skrbno spremljati na poslabšanje njihove klinične slike med uvajanjem zdravljenja z interferonom beta-1a.
Possible symptoms resulting from these changes could include tiredness, reduced ability to fight infection, bruising or unexplained bleeding. 
Možni znaki, ki se lahko pojavijo kot posledica teh sprememb, so utrujenost, zmanjšana odpornost na okužbe, podplutbe ali nepojasnjene krvavitve.
In case of severe or persistent undesirable effects, the dose of Rebif may be temporarily lowered or interrupted, at the discretion of the physician. 
V primeru hudih ali vztrajnih neželenih učinkov, se lahko po presoji zdravnika, odmerek zdravila Rebif začasno zmanjša ali ukine.
The patients enrolled into the trial had at least two clinically silent lesions on the T2-weighted MRI scan, with a size of at least 3 mm, at least one of which is ovoid or periventricular or infratentorial. 
Bolniki, vključeni v preskušanje, so imeli vsaj dve klinično tihi leziji na s T2 uteženem magnetno-resonančnem slikanju velikosti vsaj 3 mm, od katerih je vsaj ena ovoidna ali periventrikularna ali infratentorialna.
Time to peak concentrations following a single subcutaneous injection were 24 to 48 hours for neopterin, beta-2-microglobulin and 2'5'OAS, 12 hours for MX1 and 24 hours for OAS1 and OAS2 gene expression. 
Čas do največje koncentracije po eni subkutani injekciji je bil 24 do 48 ur za neopterin, beta-2-mikroglobulin in 2'5'OAS, 12 ur za MX1 in 24 ur za izraženost gena OAS1 in OAS2.
You should not stop or alter the medication without your doctor's advice. 
Zdravljenja ne smete prekiniti ali spreminjati, ne da bi se predhodno posvetovali s svojim zdravnikom.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 04 May 1998 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 04. maj 1998 Datum zadnjega podaljšanja: 04. maj 2008
Anaphylactic reactions* 
anafilaktične reakcije*
It may cause toxic reactions and allergic reactions in infants and children up to 3 years old. 
Lahko povzroči toksične reakcije in alergijske reakcije pri dojenčkih in otrocih do 3. leta starosti.
Use in children and teenagers (2 to 17 years old) No formal clinical studies have been conducted in children or teenagers. 
Uporaba pri otrocih in mladostnikih (starih 2 do 17 let) Formalnih kliničnih preskušanj pri otrocih ali mladostnikih niso izvedli.
Patients exhibiting depression should be monitored closely during therapy with Rebif and treated appropriately. 
Bolnike, ki kažejo znake depresije, moramo med zdravljenjem z zdravilom Rebif skrbno nadzorovati in jih ustrezno zdraviti.
These changes in the thyroid activity are almost always not felt by the patient as symptoms; however your doctor may recommend testing as appropriate. 
Simptomov, ki kažejo na spremembe aktivnosti ščitnice, bolniki skoraj nikoli ne opazijo, zdravnik pa lahko svetuje ustrezna testiranja.
Injection site inflammation, injection site reaction, influenza-like symptoms 
vnetje na mestu injiciranja, reakcija na mestu injiciranja, gripi podobni simptomi
Central nervous system-related adverse events associated with the use of interferon beta (e.g. dizziness) might influence the patient's ability to drive or use machines (see section 4.8). 
Neželeni dogodki v povezavi z uporabo interferona beta, vezani na osrednji živčni sistem (npr. omotica), lahko vplivajo na bolnikovo sposobnost za vožnjo ali upravljanje strojev (glejte poglavje 4.8).
• Hold RebiSlide in place until “0” appears in the dose window, then wait 10 seconds before removing the needle from the skin. 
• Držite pripomoček RebiSlide na mestu dokler se v oknu za odmerek ne prikaže »0«, nato počakajte 10 sekund, preden odstranite iglo iz kože.
If you get some or all of these symptoms: - foamy urine - fatigue - swelling, particularly in the ankles and eyelids, and weight gain. 
Če se pojavijo nekateri ali vsi od teh simptomov: - penjenje urina, - utrujenost, - oteklina, zlasti gležnjev in vek, ter povečanje telesne mase.
Rebif must then be returned to the refrigerator and used before the expiry date. 
Nato mora zdravilo Rebif postaviti nazaj v hladilnik in ga uporabiti do datuma izteka roka uporabnosti.
If the patient population was divided into 2 subgroups (those with and those without relapses in the 2-year period prior to study entry), there was no effect on disability in patients without relapses, but in patients with relapses, the proportion with progression in disability at the end of the study was reduced from 70% (placebo) to 57% (Rebif 22 micrograms and 44 micrograms combined). 
Če so razdelili populacijo bolnikov v dve podskupini (na bolnike z in brez pojava zagonov v 2 letih pred vključitvijo v študijo), ni bilo pomembnega učinka na razvoj nesposobnosti pri bolnikih brez zagonov, vendar pa se je pri bolnikih z zagoni delež tistih z napredovalo nesposobnostjo na koncu študije zmanjšal iz 70 % (placebo) na 57 % (zdravilo Rebif 22 mikrogramov v kombinaciji z zdravilom Rebif 44 mikrogramov).
• Inflammation of the fatty tissue under the skin (panniculitis), which can make the skin feel hard and possibly develop painful red lumps or patches. 
• vnetje maščobnega tkiva pod kožo (panikulitis), zaradi česar se lahko pojavi občutek otrdele kože, lahko pa se razvijejo tudi boleče rdeče bule ali lise.